Compare Adaptive Biotechnologies Corp (ADPT) vs Goodyear Tire & Rubber Co (GT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Goodyear Tire & Rubber Co — how do they compare? Adaptive Biotechnologies Corp trades at $25.15 (market cap $4.04B), while Goodyear Tire & Rubber Co trades at $5.95 (market cap $1.75B). The key difference: Adaptive Biotechnologies Corp is far larger — about 2.3× Goodyear Tire & Rubber Co's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Goodyear Tire & Rubber Co nearer its low. Which is the better fit depends on your goals.
| ADPT | GT | |
|---|---|---|
Market Cap | $4.04B | $1.75B |
Sector | Health | Consumer Cyclical |
52-Week High | $25.45 | $10.54 |
52-Week Low | $12.30 | $5.58 |
Enterprise Value | $4.10B | $9.11B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $25.45, up 2.09% today, near its 52-week high. The stock shows bullish technical signals with support at $25 and resistance at $26. Revenue growth accelerated to $277M in 2025, though net losses persist. Recent news highlights a strategic separation of its MRD and Immune Medicine businesses, aiming to unlock value.
Outlook is cautiously optimistic with 65% analyst buy ratings and a $25.50 price target. Key opportunities include MRD segment profitability and separation benefits, while risks involve sustained losses, competitive pressures, and execution challenges in the business split.
Goodyear Tire & Rubber (GT) trades at $6.03, down 6.37% over 24 hours, reflecting bearish technical signals and weak fundamentals. The stock shows negative profitability with a net income margin of -14.37% and ROE of -63.93% as of 2025, while recent Q2 2026 earnings missed on EPS but beat revenue estimates. Cash flow improved to a net $46 million in 2025, yet debt levels remain elevated with a debt-to-asset ratio of 34.36%.
Outlook remains challenging due to volume pressures and high costs, though analyst consensus leans hold (50%) with some buy support (34.62%). Key risks include sustained losses, competitive pressures, and macroeconomic headwinds impacting tire demand, requiring careful monitoring of turnaround efforts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Goodyear Tire & Rubber Co
Goodyear Tire & Rubber Co manufactures and sells a variety of rubber tires under the Goodyear brand name. The firm's tires are used for automobiles, trucks, buses, aircraft, motorcycles, mining equipment, farm equipment, and industrial equipment.
Read more on GT →
